Comorbid medical illness in bipolar disorder

Liz Forty, Anna Ulanova, Lisa Jones, Ian Jones, Katherine Gordon-Smith, Christine Fraser, Anne Farmer, Peter McGuffin, Cathryn M. Lewis, Georgina M. Hosang, Margarita Rivera and Nick Craddock

Background

Individuals with a mental health disorder appear to be at increased risk of medical illness.

Aims

To examine rates of medical illnesses in patients with bipolar disorder (n = 1720) and to examine the clinical course of the bipolar illness according to lifetime medical illness burden.

Method

Participants recruited within the UK were asked about the lifetime occurrence of 20 medical illnesses, interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) and diagnosed according to DSM-IV criteria.

Results

We found significantly increased rates of several medical illnesses in our bipolar sample. A high medical illness burden was associated with a history of anxiety disorder, rapid cycling mood episodes, suicide attempts and mood episodes with a typically acute onset.

Conclusions

Bipolar disorder is associated with high rates of medical illness. This comorbidity needs to be taken into account by services in order to improve outcomes for patients with bipolar disorder and also in research investigating the aetiology of affective disorder where shared biological pathways may play a role.

Declarations of interest

None.

Estimates suggest that those with serious mental illness are now dying approximately 25 years earlier than the general population and that up to 60% of premature deaths in those with serious mental illness are as a result of general medical conditions. Studies have shown that not only do patients with mood disorders have a greater medical ill health burden than mentally healthy individuals, but also a greater medical illness burden (a greater number of medical illnesses) seems to be associated with a more severe clinical presentation of the mood illness. Traditionally, the high prevalence of medical illness in those with mental health problems has been viewed as a consequence of psychotropic medications and an unhealthy lifestyle. However, recent research has suggested that exposure to psychotropic medication does not worsen mortality risk in patients with psychiatric illness and that there may be underlying biological mechanisms linking mood disorder and many medical illnesses.

We have previously described the rates of physical disorders in large samples of patients with recurrent depression (n = 1547) and psychiatrically healthy controls (n = 884). The current study will examine the rates of physical disorders in a large, well-defined, sample of patients with bipolar affective disorder. These patients were recruited and assessed using the same standardised procedures as our recurrent depression and control participants mentioned above. This will allow us to directly compare the rates of each physical illness in our newly recruited bipolar sample with our previously described recurrent depression and control samples. In addition, the current study will investigate whether the presence of medical illness in individuals with bipolar disorder is associated with a more severe bipolar illness course. This is the first study in a UK clinical population to assess rates of physical illnesses in patients with a diagnosis of bipolar disorder and make direct comparisons with unipolar and control samples.

Method

Participants

Participants were recruited at three UK sites (Birmingham, Cardiff and London) as part of ongoing molecular genetic and clinical studies of affective disorders. Individuals meeting DSM-IV and ICD-10 criteria for bipolar disorder (n = 1720) were included in the study. All participants were aged 18 years or older and, because they were recruited for molecular genetic studies, they were required to be of White European ethnicity. Individuals were excluded if they: (a) had a lifetime diagnosis of intravenous drug dependency; (b) had only experienced affective illness as a result of alcohol or substance dependence; (c) had only experienced affective illness secondary to medical illness or medication; or (d) were biologically related to another study participant. After complete description of the study to participants, written informed consent was obtained.

Study assessment

Participants were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). Psychiatric and family practice case-notes were reviewed for the majority of participants. Based on the SCAN interview information, and where available the case-note information, lifetime diagnoses were made according to DSM-IV and ICD-10 and ratings were made for key clinical variables (for example, age at onset, presence of psychosis). Where there was doubt regarding the diagnostic and clinical ratings the case was rated independently by two research psychologists/psychiatrists and consensus was reached. Regular interrater reliability meetings were held within and across the three sites to ensure consistency in diagnostic and ratings procedures.

 Interrater reliability was formally assessed using joint ratings for a subset of 20 participants with a range of mood disorder diagnoses. Mean overall kappa statistics of 0.85 and 0.83 were obtained for DSM-IV and ICD-0 diagnoses, respectively. Mean kappa statistics and intraclass correlation coefficients (ICCs) for other key clinical variables ranged from 0.81 to 0.99 and 0.85 to 0.97, respectively.

In order to establish the lifetime presence of physical health disorders, a short self-report questionnaire was completed by participants asking whether they had ever been told by a health professional that they have any of the following 20 health problems:

- Headaches
- Back pain
- Arthritis
- Diabetes
- High blood pressure
- Heart disease
- Lung disease
- Asthma
- Heart attack
- Stroke
- Cancer
- Cancer treatment
- Ulcer
- Infection
- Lung infection
- Eye disease
- Ear disease
- Nerve disease
- Kidney disease
- Liver disease
- Learning disability

Participants were asked whether or not they had ever been asked about any of these conditions by a health professional
Forty et al.

cofactors in the logistic regression models and the Bonferroni
the bipolar II disorder (bipolar II) group using chi-squared tests
medical conditions in the bipolar I disorder (bipolar I) group and
We then compared the lifetime prevalence of each of the different
Rates of medical illness according to bipolar subtype
incongruent psychosis or psychosis outside of mood episodes.

The control group (n = 1340) were recruited to the London
site via the Medical Research Council (MRC) general practice
research framework (n = 846) or were staff or student volunteers
of King's College London (n = 494). Individuals were included if
they were 18 years or older and were of White European origin.
Control participants recruited via the MRC general practice
research framework were screened using the Sham et al.16
 composite index (G) of depressive and anxiety symptoms and
then telephone interviewed using the Past History Schedule
(PHS)17 to screen for lifetime absence of psychiatric disorder.
The volunteers from King's College London were interviewed
in person and screened using the PHS (n = 494).

The control group also completed the short self-report
medical illness questionnaire described above.

Data analysis
Rates of medical illnesses across the bipolar, unipolar and control groups.

Sociodemographic characteristics were compared between the bipolar, unipolar and control groups using chi-squared tests for
categorical variables and Kruskal–Wallis tests for non-parametric
continuous variables. Group comparisons of the lifetime prevalence
of each of the different medical conditions were performed using
chi-squared tests and pair-wise binary logistic regression analyses
for each medical condition, with diagnostic group as the outcome
variable. As there were significant gender differences between the
three groups, gender was also entered into the logistic regression
variables. A cut-off of three or more medical illnesses was selected
as previous studies have shown that patients with multiple
conditions (defined as three or more medical conditions) are
significantly more likely to have a mental illness18 and that, when
focusing on the number of either medical or psychiatric illnesses,
the lifetime presence of three or more conditions is associated
with increased disability, lower life expectancy and increased
health spending.19

A binary logistic regression analysis was carried out with
group status (bipolar+3M/bipolar+0M) as the outcome variable.
Gender, age at interview and the clinical features that were
differently significant between the two groups (P < 0.05) in the
univariate analyses were entered as cofactors to establish which
clinical features best predicted medical illness burden group status.
All analyses were undertaken using the Statistical Procedures for
the Social Sciences (SPSS) version 20 for Windows.

Results
The control group (n = 1340) was significantly younger at
interview compared with the bipolar (n = 1720) and unipolar
(n = 1737) groups (bipolar, unipolar > control: P < 0.0001). The
median age at interview (and range) in years for the bipolar,
unipolar, and control groups was 47 (18–84), 47 (18–85) and 44
(18–91), respectively. The proportion of women was higher in
the bipolar and unipolar groups compared with the control group
(bipolar, unipolar > control: P < 0.0001), with women comprising
70%, 71% and 57% of the bipolar, unipolar and control groups
respectively.

Rates of medical illnesses across the bipolar, unipolar and control groups
The lifetime rates of self-reported medical illnesses in the bipolar, unipolar and control groups are shown in Table 1. Significant
differences between groups were found in the lifetime prevalence
of all medical illnesses with the exception of type 1 diabetes.

To examine differences in the rate of each medical illness
between the three groups, accounting for gender and age at
interview, binary logistic regression was carried out for all medical
illnesses showing a significant (P < 0.05) between-group difference
in the univariate analyses. Diagnostic group was entered as the
outcome variable and presence/absence of the medical disorder,
gender and age at interview were entered as cofactors. Odds ratios,
95% confidence intervals and P-values for each logistic regression
analysis are shown in Table 2. Following correction for multiple
testing, using the Bonferroni method, statistically significant
differences in the rates of ten medical illnesses remained between
the three groups (Fig. 1).
Comorbid medical illness in bipolar disorder

Rates of medical illness according to bipolar subtype

Table 3 shows the lifetime rates of self-reported medical illness according to bipolar subtype and the results of the binary logistic regression analyses with diagnostic group (bipolar I vs. bipolar II) as the outcome variable and presence/absence of each medical disorder, gender and age at interview as cofactors. The rates of gastric ulcers, heart disease, Parkinson's disease and rheumatoid arthritis were significantly higher in the bipolar II group. There was a significantly higher rate of kidney disease in the bipolar I group. These differences were not statistically significant following correction for multiple testing using the Bonferroni method.

### Table 1

<table>
<thead>
<tr>
<th>Medical illness</th>
<th>Bipolar group, % (n = 1720)</th>
<th>Unipolar group, % (n = 1737)</th>
<th>Control group, % (n = 1340)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>19.2</td>
<td>13.1</td>
<td>10.7</td>
</tr>
<tr>
<td>Cancer³</td>
<td>3.6</td>
<td>4.5</td>
<td>2.7</td>
</tr>
<tr>
<td>Diabetes type 1</td>
<td>1.2</td>
<td>1.2</td>
<td>0.8</td>
</tr>
<tr>
<td>Diabetes type 2</td>
<td>4.8</td>
<td>2.7</td>
<td>1.0</td>
</tr>
<tr>
<td>Elevated lipids</td>
<td>19.2</td>
<td>9.7</td>
<td>5.3</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>3.4</td>
<td>2.0</td>
<td>0.5</td>
</tr>
<tr>
<td>Gastric ulcers⁴</td>
<td>4.5</td>
<td>4.8</td>
<td>1.2</td>
</tr>
<tr>
<td>Heart disease</td>
<td>2.6</td>
<td>3.5</td>
<td>1.1</td>
</tr>
<tr>
<td>Hypertension</td>
<td>15.0</td>
<td>16.8</td>
<td>6.2</td>
</tr>
<tr>
<td>Kidney disease</td>
<td>3.0</td>
<td>1.7</td>
<td>1.1</td>
</tr>
<tr>
<td>Liver disease</td>
<td>1.2</td>
<td>2.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Memory loss/dementia</td>
<td>2.0</td>
<td>1.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Migraine headaches</td>
<td>23.7</td>
<td>21.9</td>
<td>16.5</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>0.5</td>
<td>7.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>10.8</td>
<td>10.9</td>
<td>3.0</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>2.6</td>
<td>3.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>0.6</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>4.4</td>
<td>4.3</td>
<td>2.0</td>
</tr>
<tr>
<td>Stroke</td>
<td>2.5</td>
<td>1.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Thyroid disease²</td>
<td>12.9</td>
<td>8.2</td>
<td>2.5</td>
</tr>
</tbody>
</table>

a. Data only available for a subset of the bipolar disorder group (n = 1216).

### Table 2

<table>
<thead>
<tr>
<th>Medical illness</th>
<th>Bipolar/unipolar group</th>
<th>Bipolar/control group</th>
<th>Unipolar/control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>P</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>Asthma</td>
<td>1.60 (1.33–1.93)</td>
<td>5.67 × 10⁻⁷</td>
<td>2.17 (1.74–2.71)</td>
</tr>
<tr>
<td>Cancer</td>
<td>0.79 (0.59–1.16)</td>
<td>0.224</td>
<td>1.36 (0.78–2.36)</td>
</tr>
<tr>
<td>Diabetes type 1</td>
<td>0.98 (0.53–1.81)</td>
<td>0.936</td>
<td>1.56 (0.73–3.36)</td>
</tr>
<tr>
<td>Diabetes type 2</td>
<td>1.87 (1.30–2.70)</td>
<td>0.001</td>
<td>4.14 (2.28–7.53)</td>
</tr>
<tr>
<td>Elevated lipids</td>
<td>2.33 (1.90–2.86)</td>
<td>6.46 × 10⁻¹⁶</td>
<td>3.52 (2.66–4.64)</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>1.73 (1.13–2.65)</td>
<td>0.012</td>
<td>6.19 (2.79–13.73)</td>
</tr>
<tr>
<td>Gastric ulcers</td>
<td>0.95 (0.66–1.35)</td>
<td>0.76</td>
<td>4.53 (2.21–9.30)</td>
</tr>
<tr>
<td>Heart disease</td>
<td>0.71 (0.47–1.06)</td>
<td>0.095</td>
<td>1.75 (0.95–3.21)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.89 (0.73–1.07)</td>
<td>0.210</td>
<td>2.16 (1.65–2.83)</td>
</tr>
<tr>
<td>Kidney disease</td>
<td>1.86 (1.13–3.07)</td>
<td>0.015</td>
<td>4.66 (2.03–10.66)</td>
</tr>
<tr>
<td>Liver disease³</td>
<td>0.47 (0.24–0.93)</td>
<td>0.029</td>
<td>1.01 (0.40–2.55)</td>
</tr>
<tr>
<td>Memory loss/dementia</td>
<td>1.13 (0.69–1.85)</td>
<td>0.625</td>
<td>24.3 (3.29–178.8)</td>
</tr>
<tr>
<td>Migraine headaches</td>
<td>1.13 (0.96–1.33)</td>
<td>0.147</td>
<td>1.39 (1.15–1.69)</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>0.06 (0.03–0.129)</td>
<td>4.34 × 10⁻¹⁴</td>
<td>7.01 (0.86–57.21)</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>0.99 (0.79–1.25)</td>
<td>0.950</td>
<td>2.65 (1.84–3.82)</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>0.89 (0.59–1.34)</td>
<td>0.564</td>
<td>1.75 (0.91–3.30)</td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>5.7 (1.26–25.79)</td>
<td>0.024</td>
<td>5.97 (0.76–46.92)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>1.04 (0.74–1.44)</td>
<td>0.839</td>
<td>1.92 (1.19–3.10)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.49 (0.91–4.43)</td>
<td>0.113</td>
<td>5.60 (1.98–15.83)</td>
</tr>
<tr>
<td>Thyroid disease²</td>
<td>1.70 (1.32–2.18)</td>
<td>3.31 × 10⁻⁵</td>
<td>6.26 (3.77–10.40)</td>
</tr>
</tbody>
</table>

a. Results in bold are statistically significant at P < 0.05.
b. Data only available for a subset of the bipolar disorder group (n = 1216).
Clinical characteristics of bipolar disorder according to medical illness burden

In order to investigate whether a greater burden of medical illness is associated with a more severe bipolar illness course, we compared those participants who had a history of three or more medical illnesses (bipolar+3M: \( n = 202 \)) with those with no medical illnesses (bipolar+0M: \( n = 440 \)) (Table 4, see online Table DS1 for a more detailed version of this table). A number of variables appeared to be associated with an increase in medical illness burden. These included: a longer illness duration, a typically acute onset of mood episodes, a greater number of psychiatric in-patient admissions, deterioration in functioning, increased rates of anxiety disorder, suicide attempt, rapid cycling, and treatment with anxiolytics, mood stabilisers and electroconvulsive therapy (ECT). When controlling for age at interview, the association with each of the following three variables was no longer statistically significant: number of admissions, lifetime treatment with mood stabiliser or ECT.

**Table 3** Lifetime rates (%) of self-reported medical illness according to bipolar subtype and binary logistic regression with diagnostic group (bipolar I v. bipolar II) as the outcome variable and presence/absence of the medical disorder, gender and age at interview as cofactors (prior to Bonferroni correction)

<table>
<thead>
<tr>
<th>Medical illness</th>
<th>Bipolar I, % (n = 856, 70.4%)</th>
<th>Bipolar II, % (n = 360, 29.6%)</th>
<th>OR (95% CI)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>19.5</td>
<td>19.2</td>
<td>0.98 (0.72–1.35)</td>
<td>0.909</td>
</tr>
<tr>
<td>Cancer</td>
<td>3.7</td>
<td>3.3</td>
<td>1.10 (0.55–2.19)</td>
<td>0.795</td>
</tr>
<tr>
<td>Diabetes type 1</td>
<td>0.6</td>
<td>1.1</td>
<td>1.83 (0.49–6.89)</td>
<td>0.373</td>
</tr>
<tr>
<td>Diabetes type 2</td>
<td>4.3</td>
<td>3.9</td>
<td>0.97 (0.52–1.86)</td>
<td>0.966</td>
</tr>
<tr>
<td>Elevated lipids</td>
<td>20.9</td>
<td>19.7</td>
<td>1.01 (0.73–1.40)</td>
<td>0.944</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>2.1</td>
<td>2.2</td>
<td>1.08 (0.47–2.50)</td>
<td>0.853</td>
</tr>
<tr>
<td>Gastric ulcers</td>
<td><strong>3.6</strong></td>
<td><strong>6.4</strong></td>
<td><strong>1.98 (1.13–3.47)</strong></td>
<td><strong>0.017</strong></td>
</tr>
<tr>
<td>Heart disease</td>
<td><strong>1.6</strong></td>
<td><strong>3.1</strong></td>
<td><strong>2.45 (1.07–5.60)</strong></td>
<td><strong>0.034</strong></td>
</tr>
<tr>
<td>Hypertension</td>
<td>13.1</td>
<td>15.1</td>
<td>1.30 (0.91–1.88)</td>
<td>0.152</td>
</tr>
<tr>
<td>Kidney disease</td>
<td><strong>3.9</strong></td>
<td><strong>0.8</strong></td>
<td><strong>0.24 (0.07–0.80)</strong></td>
<td><strong>0.020</strong></td>
</tr>
<tr>
<td>Liver disease</td>
<td>1.1</td>
<td>1.4</td>
<td>1.69 (0.49–5.89)</td>
<td>0.41</td>
</tr>
<tr>
<td>Memory loss/dementia</td>
<td>1.4</td>
<td>2</td>
<td>1.32 (0.49–1.32)</td>
<td>0.587</td>
</tr>
<tr>
<td>Migraine headaches</td>
<td>20.6</td>
<td>23</td>
<td>1.17 (0.86–1.59)</td>
<td>0.313</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>0.2</td>
<td>0</td>
<td>0.00 (0.00)</td>
<td>0.999</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>9.8</td>
<td>10.4</td>
<td>1.32 (0.85–2.05)</td>
<td>0.214</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>1.9</td>
<td>1.4</td>
<td>0.94 (0.34–2.60)</td>
<td>0.934</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td><strong>0.1</strong></td>
<td><strong>0.8</strong></td>
<td><strong>10.45 (1.06–102.6)</strong></td>
<td><strong>0.044</strong></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td><strong>2.6</strong></td>
<td><strong>4.5</strong></td>
<td><strong>2.05 (1.05–4.00)</strong></td>
<td><strong>0.035</strong></td>
</tr>
<tr>
<td>Stroke</td>
<td>1.8</td>
<td>2</td>
<td>1.18 (0.45–3.12)</td>
<td>0.739</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>13.3</td>
<td>11.9</td>
<td>0.99 (0.66–1.49)</td>
<td>0.982</td>
</tr>
</tbody>
</table>

*a. Results in bold are statistically significant at \( P < 0.05 \).*
To identify the clinical characteristics of bipolar illness that best predict medical illness burden group, we entered the variables that were statistically significant at the \( P < 0.05 \) level in the univariate analyses, shown in Table 4, into a logistic regression model. Age at interview and gender were also entered into the model. The clinical characteristics that best predicted high medical illness burden group, we entered the variables that were statistically significant at the \( P = 0.0001 \), rapid cycling \( P = 0.001 \), suicide attempt \( P = 0.005 \) and mood episodes with a typically acute onset \( P = 0.012 \). Suicide attempt present lifetime ever, \( n = 215 (48.9) \) vs \( 124 (61.4) \), \( P = 0.02 \), rapid cycling present lifetime ever, \( n = 99 (33.2) \) vs \( 59 (45.4) \), \( P = 0.11 \), deterioration in functioning, \( n = 143 (39.7) \) vs \( 81 (52.9) \), \( P = 0.004 \), and ever taken anxiolytics, \( n = 258 (61.9) \) vs \( 138 (75.8) \), \( P = 0.001 \). The increased rates of hypertension in our affective disorders samples are again consistent with previous research, although rates across studies vary according to the age ranges of participants. The literature concerning the relationship between mood disorders and cholesterol levels is inconsistent, with studies suggesting that lower levels are associated with current suicide risk.

### Table 4 Clinical features and course of bipolar illness in participants with bipolar disorder with a high burden of comorbid medical illness (three or more medical illnesses, bipolar+3M) compared with those participants with bipolar disorder with no history of medical illness (bipolar+0M) (see online Table DS1 for a more detailed version of this table)

<table>
<thead>
<tr>
<th>DSM-IV, ( n ) (%)</th>
<th>Bipolar+0M ( n=440 )(^a)</th>
<th>Bipolar+3M ( n=202 )(^a)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illness duration, years: median (IQR) range</td>
<td>19 (1–5) 16</td>
<td>32 (4–5) 14.75</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Onset of mood episodes typically acute, within a week, ( n ) (%)</td>
<td>Yes: 41 (9.3)</td>
<td>32 (15.8)</td>
<td>0.012</td>
</tr>
<tr>
<td>Total number of psychiatric admissions lifetime ever</td>
<td>Median (mean) 2 (2)</td>
<td>2 (4.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Anxiety disorder present lifetime ever, ( n ) (%)</td>
<td>Yes: 193 (49.9)</td>
<td>145 (75.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Suicide attempt present lifetime ever, ( n ) (%)</td>
<td>Yes: 215 (48.9)</td>
<td>124 (61.4)</td>
<td>0.002</td>
</tr>
<tr>
<td>Rapid cycling present lifetime ever, ( n ) (%)</td>
<td>Yes: 99 (33.2)</td>
<td>59 (45.4)</td>
<td>0.111</td>
</tr>
<tr>
<td>Deterioration in functioning, ( n ) (%)</td>
<td>Yes: 143 (39.7)</td>
<td>81 (52.9)</td>
<td>0.004</td>
</tr>
<tr>
<td>Ever taken anxiolytics, ( n ) (%)</td>
<td>Yes: 258 (61.9)</td>
<td>138 (75.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Electroconvulsive therapy, ( n ) (%)</td>
<td>Yes: 64 (14.8)</td>
<td>57 (29.8)</td>
<td>0.000016</td>
</tr>
</tbody>
</table>

a. For some variables because of missing data \( n \) is less than \( n = 440 \) and \( n = 202 \) for BD+0M and BD+3M, respectively.

### Discussion

#### Rates of medical illnesses across the bipolar, unipolar and control groups

The most prevalent medical conditions in the bipolar sample were migraine headache (23.7%), asthma (19.2%), elevated lipids (19.2%), hypertension (15%), thyroid disease (12.9%) and osteoarthritis (10.8%). The same six conditions were also the most prevalent conditions in the unipolar sample: migraine headache (21.9%), asthma (13.1%), elevated lipids (9.7%), hypertension (16.8%), thyroid disease (8.2%) and osteoarthritis (10.9%).

The high rates of migraine headache in these samples are consistent with previous findings. The high comorbidity between affective disorder and migraine may be because of a causal relationship, with one disorder causing (or increasing risk for) the other, or may be because of shared aetiological factors. As studies show that the combination of these two disorders cause more impairment than either disorder alone it is important to make sure that the patients are screened and treated appropriately to ensure the optimal outcome for the patient.

Almost a fifth of our bipolar sample (19.2%) self-reported a lifetime history of asthma. This figure is comparable to the rate of 15.9% reported by McIntyre et al in their bipolar sample. A recent study has suggested that childhood asthma increases the risk of bipolar disorder developing in adulthood. Again this leads to a number of hypotheses regarding the relationship between affective disorders and asthma in terms of aetiology and causation, with the possibility, for example, that carbon dioxide hypersensitivity and corticosteroid therapy may partly explain this association.

The increased rates of hypertension in our affective disorders samples are again consistent with previous research, although rates across studies vary according to the age ranges of participants. D’Mello found that hypertension seemed to be related to the severity of illness in bipolar disorder with increased levels of hypertension found in those patients with higher levels of mania.

The literature concerning the relationship between mood disorders and cholesterol levels is inconsistent, with studies suggesting that lower levels are associated with current suicide risk.
and depressive and manic symptoms, but that people with bipolar disorder are at higher risk of metabolic abnormalities including obesity and hyperlipidaemia, consistent with the increased rates of hyperlipidaemia found in our bipolar sample. Our finding of increased rates of thyroid disorder in those with mood disorders is not surprising, given the well-established link between thyroid dysfunction and mood disorders. Thyroid problems are a common side-effect of the drug lithium, which is a common treatment for bipolar disorder and is also used to treat severe or treatment-resistant unipolar depression. In our bipolar sample, rates of thyroid disorder were significantly increased in those who had taken mood stabilising medication during their lifetime.

A recent study highlighted that the amount of pain people with osteoarthritis feel appears to be directly related to their mental health, however, our study, which found significantly higher rates of osteoarthritis in patients with mood disorders compared with controls, is the first to examine the rates of osteoarthritis in people with unipolar and bipolar disorders. Studies have shown increased rates of depression in patients with arthritis (of any type) with the temporal relationship indicating that arthritis predicts new onset of psychiatric disorder. The results of previous studies have been conflicting in terms of investigating the relationship between osteoporosis and mood disorder. This is the largest study to date to examine rates of osteoporosis in bipolar disorder and we found no distinction between the bipolar, unipolar and control samples in terms of the rate of osteoporosis.

We found higher rates of kidney disease in the bipolar sample compared with controls, with rates being highest in patients with bipolar I compared with bipolar II disorder. Again, this finding is consistent with previous research and is not surprising, given the adverse renal effects that have been associated with lithium therapy, which vary from the more common reversible polyuria to irreversible kidney damage. Similarly, the increased rate of Parkinson’s disease reported in our bipolar sample compared with the unipolar sample and controls may be related to the greater use of antipsychotic medications and selective serotonin reuptake inhibitors in the bipolar sample, in that patients may be reporting symptoms occurring as a side-effect of their medication, rather than Parkinson’s disease.

Our finding of increased rates of epilepsy in the bipolar group compared with controls is consistent with previous research including a study indicating that the rate of bipolar spectrum disorders in individuals with epilepsy is higher than that seen in the general population. In our study, multiple sclerosis was significantly more common in those with unipolar disorder compared with those with bipolar disorder and controls, with the rates being 7%, 0.5%, 0%, respectively; a finding not previously described. However, this finding is consistent with previous reports that have found the prevalence of major depression to be elevated in people with multiple sclerosis compared with those without multiple sclerosis and those reporting other chronic conditions. Recent studies have suggested that biological processes may account for the overlap between depression and multiple sclerosis, rather than depression simply being a psychological reaction to the burden of being ill.

### Rates of medical illness according to bipolar subtype

To our knowledge, this is the first study to look at rates of medical comorbidities across large samples of patients with bipolar I and II disorders. In patients with bipolar disorder, the type of bipolar disorder (I or II) may be associated with an increased risk of certain medical illnesses. Participants with bipolar II disorder may be more likely to have gastric ulcers, heart disease, Parkinson’s disease and rheumatoid arthritis than patients with a diagnosis of bipolar I disorder. Participants with bipolar I disorder were significantly more likely to have had kidney disease than those with bipolar II disorder. It is important to note, however, that the statistically significant differences between the bipolar I and II groups did not remain following correction for multiple testing.

### Clinical characteristics of bipolar disorder according to medical illness burden

We have also demonstrated that in those with bipolar disorder, a higher burden of medical illness is associated with certain clinical features indicative of a more severe illness course, with greater impairment in functioning. These results are in agreement with previously reported findings that increased medical burden is linked with more suicide attempts, older age and longer illness duration.

Previous reports have attributed poor physical health in people with mental illness to increased rates of smoking and alcohol misuse (and other lifestyle factors). In our bipolar sample, we found no statistically significant differences between the bipolar group with no history of medical illness and those with a high burden of medical illness in terms of rates of alcohol misuse or smoking. Although this finding requires further investigation it suggests that, at least in our bipolar sample, smoking and alcohol misuse may not be the most significant factors influencing susceptibility to medical illness burden. This finding is in line with the findings of Chwastiak et al, who reported no association between an increased number of medical conditions and alcohol or drug misuse in patients with schizophrenia. We found higher lifetime rates of treatment with antidepressants, mood stabilisers and ECT in those with a higher medical illness burden, although after controlling for age at interview, this finding remained only for lifetime treatment with antidepressants, which is consistent with the higher rates of anxiety disorders found in those with a higher medical illness burden.

The mechanisms underlying the relationship between mental and physical health disorders are complex, although evidence suggests that the causal relationships are likely to be bidirectional. The existence of a medical condition may be a stress that increases the risk of developing a mood episode/disorder. Similarly, the existence of an affective disorder may increase the risk of developing a medical condition.

Research findings to date suggest that affective disorders may share some aetiological factors in common with certain medical disorders. A pathway analysis of Wellcome Trust Case Control Consortium genome-wide association study data suggested that bipolar disorder and metabolic disorders, such as coronary artery disease and diabetes type 2, have strong genetic links and may share some common pathophysiological pathways. Such findings suggest that subphenotypes defined by the presence of certain comorbid medical conditions are likely to be useful in studies investigating the genetic aetiology of mood disorders. The findings of Rzetetsky et al suggest that many complex phenotypes (non-Mendelian disorders including both physical and psychiatric disorders) are probably rooted in genetic variation that is significantly shared by multiple disease phenotypes.

### Strengths and limitations

The strengths of our study include the use of large, well-defined samples of patients, recruited from throughout the UK and assessed using standardised methodology. It is important to
consider our findings in light of certain limitations. First, our rates of medical illness rely on a self-report measure. The accuracy of this self-report measure was assessed by Farmer et al.,26 where 61 patient self-reports were compared with reports from the patient’s general practitioner (GP) about the medical illnesses the patient had been treated for. Kappa statistics for self-report compared with GP report for six of the more common disorders were calculated with results as follows: asthma κ = 0.73, diabetes κ = 0.91, hypertension κ = 0.87, hypercholesterolaemia κ = 0.65, heart attack/angina κ = 0.82 and arthritis κ = 0.74. Percentage agreement between GPs and participants for the presence or absence of a medical disorder was 93%. In addition, ten of the medical illnesses included in the current study were also included in a study by Carney & Jones1 which examined in-patient and out-patient administrative claims in the USA. The rates of medical disorders seen in their bipolar and control samples were reassuringly similar to those seen in the current study.

A second limitation is that we do not have a consistent measure of body mass index (BMI), or of waist/hip ratio across all of our samples. When comparing BMI between participants with unipolar depression and controls, Farmer et al.26 found that although the two groups were similarly represented in the overweight range, the unipolar depression group were significantly overrepresented in the obese range. In the Famer et al. study, obesity was associated with an increase in self-reported rates of hypercholesterolaemia, type 2 diabetes and myocardial infarction. These findings suggest that some of the results from the current study may be altered if we were to control for BMI. Here, BMI could be seen as a confounding factor or an intermediate phenotype with potentially shared heritable pathogenesis. Third, our sample was restricted to a single ethnic group, limiting the generalisability of our findings. Fourth, it is possible that the voluntary nature of the control sample may have resulted in an unrepresentative healthy sample with an artificially low prevalence of medical illnesses. Finally, we did not have data on some additional lifestyle factors such as diet or activity that may be related to medical illness burden.

Implications

These findings suggest that patients with affective disorders have an increased risk of certain medical conditions. Knowledge of the most prevalent medical conditions in patients with affective disorders and developments in the prevention, detection and treatment of such illnesses in this group are essential in improving care and prognosis. It is important to raise awareness among healthcare professionals about the risks to which patients with affective disorders are exposed. Knowing which medical illnesses are likely to coexist with a mood disorder may help to improve diagnostics and management and therefore clinical and social care for patients. Early diagnostics and treatment of medical conditions are necessary to prevent mortality and unfavourable outcomes in terms of both physical and mental health.

Although the relationship between affective disorders and physical conditions is not fully understood, it is likely that some of the risk factors for comorbid psychiatric and medical illness are modifiable. Further research on this subject may help to improve quality of life, prognosis and life expectancy for those with these illnesses. Compared with individuals with no history of mental illness, individuals with bipolar disorder are at increased risk of premature death, from both natural and unnatural causes.27 A growing evidence base suggests that more integrated ways of working, with collaboration between mental health and other professionals, offers the best chance of improving outcomes for individuals with both mental health and physical conditions.28

Acknowledgements

The authors thank all of the participants who gave their time to participate in the study.

References

12 Cohen-Woods S, Craig I, Gaysina D, Gray J, Quastingshe C, Craddock N, et al. The Bipolar Association Case-Control Study (BACCS) and meta-analysis.


15 Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. *Arch Gen Psychiatry* 1990; 47: 589–93.


21 Lipton RB, Hameltsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, headache, social dysfunction, and migraine-related disability: a national study. *Headache* 2001; 41: 189–97.


